Efficacy and Safety Study of Moxidectin in Adults With Scabies

PHASE2CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

November 23, 2023

Primary Completion Date

November 27, 2024

Study Completion Date

February 11, 2025

Conditions
Scabies
Interventions
DRUG

Moxidectin Oral Product

The required number of moxidectin 2 mg tablet over encapsulated capsules will be administered as a single dose with placebo capsules to match as required

DRUG

Moxidectin Oral Product

The required number of moxidectin 2 mg tablet over encapsulated capsules will be administered as a single dose with placebo capsules to match as required

DRUG

Moxidectin Oral Product

The required number of moxidectin 2 mg tablet over encapsulated capsules will be administered as a single dose.

DRUG

Placebo

16 placebo capsules will be administered as a single dose.

Trial Locations (9)

21104

Derclinic, San Pedro Sula

Hospital y Clinica Bendana, San Pedro Sula

33016

Evolution Clinical Trials, Miami

33155

Advanced Care and Clinical Trials, LLC, Miami

33165

Medical Research of Westchester, Inc, Miami

33612

Affinity Clinical Research LLC, Tampa

90057

LA Universal Research Center, Inc, Los Angeles

Unknown

Instituto Dermatologico Dominicano y Cirugia de Piel, Santo Domingo Oeste

01101

Vargas Clinic, San Salvador

All Listed Sponsors
lead

Medicines Development for Global Health

OTHER

NCT05875441 - Efficacy and Safety Study of Moxidectin in Adults With Scabies | Biotech Hunter | Biotech Hunter